Clinical Trials in Cergy-Pontoise, France
4 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Rennes University Hospital386 enrolled23 locationsNCT05758831
Recruiting
Phase 3
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisEnd Stage Renal Disease
Centre Hospitalier Departemental Vendee136 enrolled58 locationsNCT03323476
Recruiting
Phase 2Phase 3
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Acute Myeloid Leukemia (AML)
University Hospital, Angers3,100 enrolled56 locationsNCT02416388
Recruiting
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
AML, Adult
French Innovative Leukemia Organisation230 enrolled42 locationsNCT06263387